29956-84-1

Upstream product

• 52159-67-8 methyl 3-chloro-2-hydroxybenzoate 
• 93820-08-7 3-chloro-2-hydroxybenzoyl chloride 
• 65-45-2 salicylamide 
• 116025-20-8 3-chloro-2-hydroxy-thiobenzoic acid S-methyl ester 
• 95-57-8 2-monochlorophenol 
• 1829-32-9 3-Chloro-2-hydroxybenzoic acid 

Downstream Products

• 1338327-05-1 2-chloro-6-cyanophenyl trifluoromethanesulfonate 

Relevant academic research and scientific papers

Continuous-Flow Hofmann Rearrangement Using Trichloroisocyanuric Acid for the Preparation of 2-Benzoxazolinone

A continuous-flow preparation of 2-benzoxazolinone via the Hofmann rearrangement of salicylamide has been implemented employing trichloroisocyanuric acid as the stable and atom-economic chlorinating agent. The system was optimized to avoid solid accumulation and allow the preparation of hundreds of grams of the pure desired material over a working day. Furthermore, a trichloroisocyanuric acid (TCCA)-based chlorination of 2-benzoxazolone to the corresponding 5-chloro derivative was also carried out under batch conditions.

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desat- urase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

A short and efficient preparation of methyl-[1,2,4]oxadiazolium derivatives with plant-inducing activity

A short and efficient preparation of methyl-[1,2,4]oxadiazolium derivatives with plant-inducing activity is discussed. A concise and efficient synthetic method leading to structurally diverse array of oxadiazolium derivatives, starting from halogenated phenols is also developed. The starting point of the synthesis is the Lewis acid mediated addition of isocyanates to phenols. The strategy also involves a new and rapid access to all meta-halogenated salicylic acids, compounds of high synthetic value.